Nasdaq
$21.30▲ 0.52%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.51BShares out 71.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 9.22After-hours26.09.23 06:594Ownership#●●●
Structure Therapeutics Inc.
Insider Coll Crespo Blas of Structure Therapeutics Inc. filed a Form 4 on September 22, 2026, reporting a change in beneficial ownership of securities as of September 18, 2026. This filing serves as an official disclosure of insider equity transactions to the SEC.…more
$21.30+0.52%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.21After-hours26.09.22 05:35144Ownership
Structure Therapeutics Inc.
Insider Coll Crespo Blas of Structure Therapeutics Inc. has filed SEC Form 144 to report a proposed sale of company securities. This filing represents a standard notification of an insider's plan to dispose of their holdings.…more
$21.30+0.52%vs prev closeView filingShare - 9.8Pre-market26.09.08 21:098-KKey event
Structure Therapeutics Inc.
Structure Therapeutics reported positive Phase 1/2a SAD clinical results for its oral amylin receptor agonist ACCG-2671, demonstrating favorable safety and target engagement. Additionally, 72-week data from the ACCESS OLE trial for aleniglipron showed up to 16.2% weight loss with consistent tolerability, supporting the ongoing Phase 3 ACCOMPLISH program.…more
$21.30+0.52%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoAfter-hours26.10.20 05:13#●●●#●●●
Structure Therapeutics to Present Aleniglipron Clinical Data at ObesityWeek 2026…more
Structure Therapeutics announced upcoming poster presentations for its oral obesity drug candidate, Aleniglipron, at the ObesityWeek conference in November. As this is a standard academic presentation announcement without new regulatory or financial milestones, the impact remains neutral.…more
$21.30+0.52%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.8Regular26.09.09 01:15
●●●●●●●● ●●●●● ●●●●●●
Structure Therapeutics announced encouraging clinical trial results for its oral weight-loss drug candidates, demonstrating significant weight reduction and favorable tolerability. Despite the positive data, the company's shares experienced a decline.…more
$21.30+0.52%vs prev closeShareBenzinga - 9.8Pre-market26.09.08 21:06
●●●●●●●● ●●●●● ●●●●●●
Structure Therapeutics announced that its obesity drug candidate Aleniglipron achieved a 16.2% weight reduction over 72 weeks in an open-label extension study. While early clinical data shows promise, further large-scale trials are required to confirm long-term efficacy.…more
$21.30+0.52%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report